Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 20, 2026, 8:43 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 51 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: Bosutinib Clear all
Recruiting No phase listed Observational

A Real-world Chronic Myelogenous Leukemia (CML) Patient Disease Registry to Describe Patient Experience and Clinical Outcomes Among Patients With CML Receiving Approved First or Second Line Tyrosine Kinase Inhibitor (TKI) Therapy

NCT07091019
View directory record Official record
Conditions
Chronic Myelogenous Leukemia - Chronic Phase
Interventions
TKIs
Other
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 100 Years
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2033
U.S. locations
17
States / cities
Birmingham, Alabama • Stockton, California • Torrance, California + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 20, 2026 · Synced Oct 20, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Letrozole Combination Versus Letrozole Alone In Post Menopausal Women With Breast Cancer

NCT00880009
View directory record Official record
Conditions
Breast Cancer
Interventions
Bosutinib, Letrozole
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
5
States / cities
Whittier, California • Joliet, Illinois • Niles, Illinois + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 27, 2021 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Bosutinib In Subjects With Renal Impairment

NCT01233882
View directory record Official record
Conditions
Renal Disease, End-Stage, Renal Insufficiency, Chronic, Renal Insufficiency, Acute
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
5
States / cities
DeLand, Florida • Gainesville, Florida • Miami, Florida + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 3, 2012 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

The Life After Stopping Tyrosine Kinase Inhibitors Study (The LAST Study)

NCT02269267
View directory record Official record
Conditions
Leukemia, Myeloid, Chronic
Interventions
Imatinib (Stopping their TKI), Dasatinib (Stopping their TKI), Nilotinib (Stopping their TKI), Bosutinib (Stopping their TKI)
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2022
U.S. locations
16
States / cities
San Francisco, California • Tampa, Florida • Atlanta, Georgia + 11 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2023 · Synced Oct 20, 2026, 8:43 PM EDT
Completed No phase listed Observational

Determining Change in Cardiovascular and Metabolic Risks in Patients With Chronic Phase Chronic Myeloid Leukemia Receiving BCR-ABL Tyrosine Kinase Inhibitor First-Line Therapy in the United States

NCT03045120
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
24
States / cities
Chicago, Illinois • Elk Grove Village, Illinois • Hoffman Estates, Illinois + 18 more
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Determine the Effect of a High-Fat Meal on the Relative Bioavailability and Pharmacokinetics of a Single Dose of Bosutinib Administered Orally to Healthy Subjects

NCT00721474
View directory record Official record
Conditions
Healthy Subjects
Interventions
Bosutinib
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Feb 6, 2009 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 1Phase 2 Interventional Results available

Phase I/II Study of Bosutinib in Combination With Inotuzumab Ozogamicin in CD22-positive PC Positive ALL and CML

NCT02311998
View directory record Official record
Conditions
B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Blasts More Than 5 Percent of Bone Marrow Nucleated Cells, CD22 Positive, Philadelphia Chromosome Positive, BCR-ABL1 Positive Chronic Myelogenous Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Inotuzumab Ozogamicin
Drug · Biological
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
22 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2022
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jul 17, 2023 · Synced Oct 20, 2026, 8:43 PM EDT
Completed No phase listed Observational

A Study to Evaluate Available Treatment Information of Ponatinib, Bosutinib, Imatinib, Dasatinib and Nilotinib in Adults With Chronic Myeloid Leukemia

NCT05743465
View directory record Official record
Conditions
Leukemia
Interventions
No Intervention
Other
Lead sponsor
Takeda
Industry
Eligibility
18 Years and older
Enrollment
1,769 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cambridge, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 2, 2023 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Evaluating Drug Interaction Between Multiple Doses of Ketoconazole and a Single Dose of SKI-606

NCT00434486
View directory record Official record
Conditions
Healthy
Interventions
SKI-606
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 12, 2007 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

NCT02551718
View directory record Official record
Conditions
Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
Interventions
Chemosensitivity Assay, Cytology Specimen Collection Procedure, Gene Expression Analysis, Genetic Variation Analysis, In Vitro Sensitivity-Directed Chemotherapy
Other · Genetic · Drug
Lead sponsor
University of Washington
Other
Eligibility
3 Years and older
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jun 30, 2022 · Synced Oct 20, 2026, 8:43 PM EDT
Active, not recruiting Phase 2 Interventional

Treatment Free Remission After Combination Therapy With Ruxolitinib Plus Tyrosine Kinase Inhibitors

NCT03610971
View directory record Official record
Conditions
Chronic Phase Chronic Myeloid Leukemia, Chronic Myeloid Leukemia, Chronic Phase
Interventions
Ruxolitinib, BCR-ABL Tyrosine Kinase Inhibitor (TKI)
Drug
Lead sponsor
H. Lee Moffitt Cancer Center and Research Institute
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2026
U.S. locations
8
States / cities
Tampa, Florida • Atlanta, Georgia • Montvale, New Jersey + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 2, 2026 · Synced Oct 20, 2026, 8:43 PM EDT
Active, not recruiting Phase 2 Interventional Results available

Testing the Addition of Ruxolitinib to the Usual Treatment (Tyrosine Kinase Inhibitors) for Chronic Myeloid Leukemia

NCT03654768
View directory record Official record
Conditions
Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions
Bosutinib, Dasatinib, Laboratory Biomarker Analysis, Nilotinib, Ruxolitinib, Imatinib
Drug · Other
Lead sponsor
SWOG Cancer Research Network
Network
Eligibility
18 Years and older
Enrollment
81 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
541
States / cities
Anchorage, Alaska • Fairbanks, Alaska • Kingman, Arizona + 320 more
Source: ClinicalTrials.gov public record
Updated Dec 18, 2025 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Not applicable Interventional Results available

Bosutinib Treatment Extension Study Only For Subjects With Chronic Myeloid Leukemia (CML) Who Have Previously Participated In Bosutinib Studies B1871006 Or B1871008

NCT01903733
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
281 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
13
States / cities
Orlando, Florida • Atlanta, Georgia • Indianapolis, Indiana + 5 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2022 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Subjects With Breast Cancer

NCT00319254
View directory record Official record
Conditions
Breast Neoplasms, Neoplasm Metastasis
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
4
States / cities
Duarte, California • Santa Monica, California • Tampa, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 31, 2013 · Synced Oct 20, 2026, 8:43 PM EDT
Recruiting No phase listed Observational

A Study to Learn About the Study Medicine Bosulif in Adult Patients With Chronic Myeloid Leukemia(CML).

NCT06297161
View directory record Official record
Conditions
Chronic Leukemia Myelogenous
Interventions
Bosulif
Drug
Lead sponsor
Pfizer
Industry
Eligibility
20 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Apr 14, 2026 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Comparing Two Different Tablet Formulations Of Bosutinib

NCT00934674
View directory record Official record
Conditions
Healthy
Interventions
SKI-606 (Bosutinib)
Drug
Lead sponsor
Wyeth is now a wholly owned subsidiary of Pfizer
Industry
Eligibility
18 Years to 50 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Sep 2, 2009 · Synced Oct 20, 2026, 8:43 PM EDT
Recruiting Phase 4 Interventional

Asciminib Roll-over Study

NCT04877522
View directory record Official record
Conditions
Chronic Myelogenous Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Interventions
Asciminib single agent, Imatinib, Nilotinib, Bosutinib, Dasatinib, Asciminib single agent pediatric formulation
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
7 Years to 100 Years
Enrollment
347 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2030
U.S. locations
6
States / cities
Ann Arbor, Michigan • New York, New York • Portland, Oregon + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 1 Interventional

Bosutinib in Combination With Pemetrexed in Patients With Selected Metastatic Solid Tumors

NCT03023319
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung, Mesothelioma, Bladder Cancer, Ovarian Cancer, Peritoneal Cancer, Thymoma, Thymus Cancer, Uterine Cervical Cancer
Interventions
Bosutinib, Pemetrexed
Drug
Lead sponsor
Nagla Abdel Karim
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Augusta, Georgia
Source: ClinicalTrials.gov public record
Updated Jun 14, 2022 · Synced Oct 20, 2026, 8:43 PM EDT
Completed No phase listed Observational

Real-World Treatment Patterns and Outcomes Among Patients With Chronic Myeloid Leukemia in Earlier Lines of Therapy

NCT06692803
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Not listed
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
2,043 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
1
States / cities
East Hanover, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 18, 2024 · Synced Oct 20, 2026, 8:43 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Study Of Bosutinib With Capecitabine In Solid Tumors And Locally Advanced Or Metastatic Breast Cancer

NCT00959946
View directory record Official record
Conditions
Advanced Breast Cancer (Parts 1 and 2), Advanced Pancreatic Cancer (Part 1), Advanced Colorectal Cancer (Part 1), Advanced Cholangiocarcinoma (Part 1), Advanced Glioblastoma Multiforme (Part 1)
Interventions
Bosutinib, Capecitabine
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Detroit, Michigan
Source: ClinicalTrials.gov public record
Updated Feb 22, 2013 · Synced Oct 20, 2026, 8:43 PM EDT
Terminated Phase 2 Interventional Results available

Study Evaluating Bosutinib-Exemestane Combination Vs Exemestane Alone in Post Menopausal Women With Breast Cancer

NCT00793546
View directory record Official record
Conditions
Advanced Breast Cancer
Interventions
Bosutinib, Exemestane
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older · Female only
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
11
States / cities
Lake Worth, Florida • Joliet, Illinois • Boston, Massachusetts + 6 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2012 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Study Evaluating SKI-606 (Bosutinib) In Philadelphia Chromosome Positive Leukemias

NCT00261846
View directory record Official record
Conditions
Chronic Myeloid Leukemia
Interventions
Bosutinib
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
571 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2015
U.S. locations
29
States / cities
Duarte, California • Denver, Colorado • Washington D.C., District of Columbia + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 27, 2017 · Synced Oct 20, 2026, 8:43 PM EDT
Completed Phase 2 Interventional Results available

Bosutinib in Adult Patients With Recurrent Glioblastoma

NCT01331291
View directory record Official record
Conditions
Glioblastoma
Interventions
bosutinib
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 25, 2016 · Synced Oct 20, 2026, 8:43 PM EDT
Active, not recruiting Phase 1Phase 2 Interventional

Bosutinib in Pediatric Patients With Newly Diagnosed Chronic Phase or Resistant/Intolerant Ph + Chronic Myeloid Leukemia

NCT04258943
View directory record Official record
Conditions
Philadelphia Chromosome Positive CML, Accelerated Phase Chronic Myelogenous Leukemia, Blastic Phase Chronic Myelogenous Leukemia, Chronic Phase Chronic Myelogenous Leukemia
Interventions
Bosutinib
Drug
Lead sponsor
Children's Oncology Group
Network
Eligibility
1 Year to 17 Years
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2028
U.S. locations
45
States / cities
Birmingham, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 41 more
Source: ClinicalTrials.gov public record
Updated Oct 1, 2026 · Synced Oct 20, 2026, 8:43 PM EDT